Becton Dickinson and Company ($BDX) Stock Forecast: Up 7.4% Today

What is Becton Dickinson and Company?

Becton Dickinson (BDX) is a global medical technology company that manufactures and sells medical devices, instrument systems, and reagents. The company is known for its contributions to healthcare and life sciences.

Why is Becton Dickinson and Company going up?

BDX stock is up 7.4% on Aug 7, 2025 13:41

• BDX stock experienced a strong bullish movement today.
• The company surpassed Q3 earnings and revenue estimates, indicating strong financial performance.
• Despite expectations of declining earnings, BDX managed to deliver positive surprises, boosting investor confidence.
• The better-than-expected performance in key metrics for the quarter ended June 2025 likely contributed to the bullish market movement.

BDX Price Chart

BDX Technical Analysis

BDX News

Becton Dickinson ( BDX ) Surpasses Q3 Earnings and Revenue Estimates

Becton Dickinson (BDX) delivered earnings and revenue surprises of +7.60% and +0.47%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?

https://www.zacks.com/stock/news/2677968/becton-dickinson-bdx-surpasses-q3-earnings-and-revenue-estimates

Curious about Becton Dickinson ( BDX ) Q3 Performance? Explore Wall Street Estimates for Key Metrics

Evaluate the expected performance of Becton Dickinson (BDX) for the quarter ended June 2025, looking beyond the conventional Wall Street top-and-bottom-line estimates and examining some of its key metrics for better insight.

https://www.zacks.com/stock/news/2661791/curious-about-becton-dickinson-bdx-q3-performance-explore-wall-street-estimates-for-key-metrics

Earnings Preview: Becton Dickinson ( BDX ) Q3 Earnings Expected to Decline

Becton Dickinson (BDX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

https://www.zacks.com/stock/news/2643953/earnings-preview-becton-dickinson-bdx-q3-earnings-expected-to-decline

Trending Today

Dogecoin ($DOGE) Crypto Forecast: Up 5.3% Today

Monero ($XMR) Crypto Forecast: Up 7.6% Today

Becton Dickinson and Company Price History

01.04.2025 - BDX Stock was down 10.3%

• Despite delivering earnings and revenue surprises in Q2, Becton Dickinson (BDX) experienced a bearish movement in its stock.
• Investors may have been anticipating stronger performance from the company, leading to a sell-off post earnings report.
• The market's negative reaction to projections for key metrics suggests concerns about the company's future growth prospects.
• Overall, the bearish movement in BDX could stem from profit-taking by investors expecting more robust results.

01.04.2025 - BDX Stock was down 14.7%

• BDX posted strong Q1 adjusted EPS, surpassing expectations, but fell short of sales forecasts, causing a negative market response.
• The company's commitment to invest $2.5 billion in enhancing US manufacturing raised concerns about potential cost increases and impacts on future profitability.
• The reduction in fiscal 2025 EPS guidance, attributed to a $0.25 tariff impact, likely influenced investor sentiment negatively.
• Despite outperforming expectations in Q2 earnings, adjustments in overall outlook and guidance appeared to dampen investor enthusiasm, leading to a decline in the stock price.

02.04.2025 - BDX Stock was down 5.0%

• The stock of Becton Dickinson (BDX) experienced a strong bearish movement.
• The potential tariff impact on the company's profit outlook for 2025, coupled with a cut in EPS guidance due to tariff hits, likely contributed to the negative market sentiment.
• Despite posting Q2 earnings that topped estimates, the missed revenue consensus and reduced EPS guidance may have overshadowed the positive earnings surprise, leading to the bearish trend.
• The technical analysis suggesting a possible capitulation in BDX could have added to the selling pressure on the stock as investors reacted to the mixed financial performance and future outlook.

02.04.2025 - BDX Stock was down 8.1%

• BDX stock displayed bearish movement on the market recently.
• Concerns about potential tariff impact on BDX's 2025 profit outlook, leading to a $0.25 decrease in EPS guidance, might have influenced the bearish sentiment.
• Despite exceeding Q2 earnings expectations, BDX fell short of sales consensus and adjusted its EPS guidance, disappointing investors and driving the bearish trend.
• Technical analysis hints at a possible capitulation in BDX, adding to the negative market sentiment and contributing to the stock's decline.

27.10.2024 - BDX Stock was down 1.0%

• BDX experienced a bearish movement possibly due to the news of Embecta, a spinoff company, stopping its insulin patch pump program and planning restructuring.
• Investors might be concerned about the implications of this decision on BDX's overall business strategy and potential impact on future revenue.
• The positive news about Embecta's financial performance and stock jump could have diverted investor attention away from BDX, leading to a decline in BDX's stock price.
• This unexpected development within the healthcare sector could have contributed to the bearish sentiment surrounding BDX today.

07.10.2024 - BDX Stock was down 5.0%

• Despite strong fourth-quarter sales and exceeding revenue estimates, BDX faced a downturn likely attributed to concerns over lower sales expectations in China and market dynamics in the bioscience and pharma sectors.
• The introduction of the BD IO Vascular Access System, designed for quick vascular access in critical care scenarios, did not offset the prevailing market sentiment towards the stock.
• Investors may be evaluating BDX against other companies like MMSI, potentially leading to selling pressure on the stock.
• Although positive earnings surprises were noted, they may not have been enough to counter broader market worries, contributing to BDX's bearish performance despite its robust financial results.

15.00.2025 - BDX Stock was down 1.7%

• The bearish movement in BDX today could be attributed to profit-taking by investors after a period of strong gains or a negative development within the company itself.
• The comparison with Alvotech (ALVO) might have highlighted potential outperformance by ALVO, leading investors to shift their focus and capital away from BDX.
• Market sentiment towards medical stocks as a whole could have shifted, impacting BDX negatively despite its strong fundamentals.
• It's essential for investors to closely monitor any updates regarding BDX's financial performance and strategic initiatives to make informed decisions in light of today's bearish movement.

06.01.2025 - BDX Stock was down 5.1%

• BDX posted impressive Q1 earnings, surpassing revenue and EPS expectations, indicating a strong performance in the last quarter.
• Despite the favorable earnings, the market responded negatively to BDX revising its forecast and revealing plans to split its Biosciences and Diagnostic Solutions business segments.
• Investors may have apprehensions regarding the consequences of this strategic decision and its potential effects on future growth and profitability, influencing the bearish market trend seen in BDX today.

07.07.2025 - BDX Stock was up 7.4%

• BDX stock experienced a strong bullish movement today.
• The company surpassed Q3 earnings and revenue estimates, indicating strong financial performance.
• Despite expectations of declining earnings, BDX managed to deliver positive surprises, boosting investor confidence.
• The better-than-expected performance in key metrics for the quarter ended June 2025 likely contributed to the bullish market movement.

03.04.2024 - BDX Stock was down 0.5%

• Despite reporting strong second-quarter sales and surpassing earnings and revenue estimates, BDX's stock experienced a bearish movement.
• The overall bullish market sentiment did not positively impact BDX on Thursday, hinting at a specific factor affecting the stock.
• Investors may have been concerned about future growth prospects or external factors despite the positive financial results.
• The contrast between optimistic analyst outlook and market movement implies underlying issues influencing investor sentiment towards BDX.

03.05.2024 - BDX Stock was up 2.4%

• BDX stock experienced a bullish movement after announcing the acquisition of Edwards Lifesciences' critical care business for $4.2 billion.
• The market reacted positively to this strategic move, as it expands BDX's portfolio and strengthens its position in the healthcare industry.
• The acquisition is seen as a smart investment by BDX to enhance its offerings and potentially drive future growth in the medical technology sector.
• This news reflects investor confidence in BDX's strategic decisions and long-term prospects, contributing to the bullish movement in the stock price.

10.06.2024 - BDX Stock was up 0.1%

• The bullish movement in BDX stock today could be attributed to the positive performance comparison with its competitors in the Health Care Equipment & Supplies industry.
• Investors may be reacting favorably to the extensive industry analysis that highlights Boston Scientific's strong market standing, growth prospects, and key financial metrics.
• The market may be optimistic about Boston Scientific's innovative products for medical procedures, such as angioplasty, cardiac rhythm management, and chronic pain treatment, which could drive future growth and profitability.